KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Neogenomics (NEO) over the last 17 years, with Q2 2025 value amounting to $458000.0.

  • Neogenomics' Gains from Investment Securities rose 42643.68% to $458000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $346000.0, marking a year-over-year increase of 846.39%. This contributed to the annual value of $207000.0 for FY2024, which is 1828.57% up from last year.
  • As of Q2 2025, Neogenomics' Gains from Investment Securities stood at $458000.0, which was up 42643.68% from -$112000.0 recorded in Q4 2024.
  • In the past 5 years, Neogenomics' Gains from Investment Securities registered a high of $458000.0 during Q2 2025, and its lowest value of -$112000.0 during Q4 2024.
  • For the 5-year period, Neogenomics' Gains from Investment Securities averaged around $89846.2, with its median value being $87000.0 (2024).
  • In the last 5 years, Neogenomics' Gains from Investment Securities plummeted by 255000.0% in 2021 and then surged by 270000.0% in 2022.
  • Quarter analysis of 5 years shows Neogenomics' Gains from Investment Securities stood at $35000.0 in 2021, then dropped by 28.57% to $25000.0 in 2022, then surged by 600.0% to $175000.0 in 2023, then plummeted by 164.0% to -$112000.0 in 2024, then soared by 508.93% to $458000.0 in 2025.
  • Its Gains from Investment Securities was $458000.0 in Q2 2025, compared to -$112000.0 in Q4 2024 and $143000.0 in Q3 2024.